Analysts Set Tyra Biosciences, Inc. (NASDAQ:TYRA) PT at $46.90

Tyra Biosciences, Inc. (NASDAQ:TYRA) has been assigned an average recommendation of “Moderate Buy” from the fourteen analysts that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and twelve have given a buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $48.2222.

A number of research analysts have issued reports on TYRA shares. JonesTrading initiated coverage on shares of Tyra Biosciences in a research note on Wednesday, June 17th. They set a “buy” rating and a $56.00 target price for the company. Jefferies Financial Group reaffirmed a “buy” rating and set a $42.00 price target on shares of Tyra Biosciences in a report on Wednesday, August 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Friday, July 17th. HC Wainwright restated a “buy” rating and issued a $45.00 target price on shares of Tyra Biosciences in a research report on Thursday, May 14th. Finally, Wolfe Research started coverage on Tyra Biosciences in a research note on Tuesday, May 19th. They set a “peer perform” rating on the stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Hilton Head Capital Partners LLC acquired a new position in Tyra Biosciences during the first quarter worth about $30,000. Caitong International Asset Management Co. Ltd acquired a new stake in Tyra Biosciences in the fourth quarter valued at approximately $51,000. Chung Wu Investment Group LLC bought a new stake in shares of Tyra Biosciences during the 4th quarter worth about $53,000. State of Wyoming bought a new position in Tyra Biosciences in the 2nd quarter worth $76,000. Finally, Canada Pension Plan Investment Board bought a new position in Tyra Biosciences in the 2nd quarter worth approximately $230,000. 84.14% of the stock is owned by institutional investors and hedge funds.

Tyra Biosciences Price Performance

Shares of TYRA opened at $25.13 on Monday. The company has a market cap of $1.50 billion, a P/E ratio of -10.47 and a beta of 0.74. The stock has a fifty day moving average price of $29.21 and a 200 day moving average price of $32.07. Tyra Biosciences has a 12 month low of $11.70 and a 12 month high of $40.65.

Tyra Biosciences (NASDAQ:TYRA) last posted its earnings results on Tuesday, August 4th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). As a group, research analysts anticipate that Tyra Biosciences will post -2.74 earnings per share for the current year.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.